Sign in
Taking people in United StatesPhase 1

Tests AG01 antibody in advanced solid tumors, including breast and lung cancers

Tests AG01 antibody in adults with advanced solid tumors.

Key facts

Who runs it
A&G Pharmaceutical Inc.
Where
Baltimore, United StatesSee the site
Trial code
Registry title
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
77 people, planned
Started
14 Feb 2022
Expected to end
Nov 2026
Type of study
Interventional, 5 groups
Treatments tested
  • AG-01 Compound
Record updated
28 November 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumours that have spread and can be measured on scans. It tests AG01, a new antibody drug, for the first time in people.

Age
18 years or older
Sex
Men and women can both join.
Disease stage
Advanced or metastatic cancer with at least 1 measurable lesion on scans. Expansion groups: triple negative breast cancer, hormone-resistant breast cancer, non small cell lung cancer, mesothelioma.
Earlier treatment
Phase 1A: the cancer came back or did not respond to 1 or more standard treatments, and no standard therapy exists. Each expansion group needs set earlier treatments. At least 4 weeks (6 weeks for mitoxantrone or mitomycin) since the last chemotherapy or radiation.
Biomarker or test result
Phase 1A: no GP88 test needed. Phase 1B: tumour tissue must show GP88 at level 1+, 2+ or 3+ on an IHC test.

Main reasons for not taking part

  • Uncontrolled illness, such as heart failure, unstable angina, poorly controlled arrhythmia, heart attack in the last 6 months
  • Uncontrolled or untreated CNS metastases, or cancer in the lining of the brain (meninges)
  • Another investigational drug or study in the 28 days before starting
  • Pregnant or breastfeeding women
  • Another cancer in the last 2 years, except in-situ cancer or treated basal or squamous cell skin cancer

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Signed informed consent/authorization is obtained prior to conducting any study-specific screening procedures
  • 18 years of age or older
  • Histologic or cytologic diagnosis of advanced cancer
  • Radiographic evidence of at least 1 measurable metastatic lesion per RECIST 1.1 criteria
  • Patients with relapsed/refractory solid tumor malignancies who failed one or more standard chemotherapy or targeted therapy regimens per SOC guidelines such as NCCN guidelines and for whom no standard therapy exists (Phase 1A). No GP88 expression pre-required for phase 1A
  • For phase 1B, patients must have GP88 tissue tumor tissue expression of 1+, 2+ or 3+ by IHC, archival tumor tissue will be used whenever possible. If no archival tissue is available, subject will be asked to consent to a study specific tumor biopsy for GP88 testing (phase1B). Patients who do not have archival tissue available for the dose expansion cohort (1B) will not be exposed to significant risk procedure to obtain tissue and may still be eligible for the study, after discussion with the Sponsor and Medical Monitor
  • At least 4 weeks after the last dose of chemotherapy or radiation therapy; 6 weeks for mitoxantrone or mitomycin therapy
  • ECOG performance status must be ≤2 (Appendix A)
  • Adequate hepatic, renal, and bone marrow function:; Absolute neutrophil count ≥ 1,000/uL Platelets ≥ 100,000/µL Total bilirubin WNL per Institution ULN AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional ULN Creatinine ≤1.2 mg/dL Clearance ≥50ml/min (Cockcroft-Gault)
  • All study participants (male and female) with reproductive potential must practice highly effective methods of contraception (failure rate <1% annually) while on this study and for 90 days after completion of study therapy
  • Men and women of all ethnic groups are eligible for this trial
  • Females at reproductive age must have a negative urine pregnancy test prior to entry to this study
  • Males with partners at reproductive age must use highly effective birth control methods to prevent partners' pregnancy while on study and for 90 days after completion of study treatments
  • Life expectancy is greater than 12 weeks
  • Subjects with triple negative breast cancer (TNBC) cohort must have received 1 or more standard of care (SOC) or targeted therapies for metastatic TNBC. If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Atezolizumab or Pembrolizumab), unless not a candidate for these therapies. If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies. is FDA approved for treatment of advanced TNBC. Prior exposure to Sacituzumab Govitecan ADC therapy does not preclude eligibility in the current study
  • Subjects with Cohort 2-Breast Cancer ER and/or PR positive, hormone-resistant breast cancer who received 1 or more hormonal (HT) therapies or HT/CD4/6 kinase inhibitor or HT/MTOR inhibitor for treatment of metastatic breast cancer are eligible. If the tumor has known PIK3CA mutation, HT/Alpelisib combination should be considered unless not a candidate for this therapy
  • Subjects with metastatic/recurrent NSCLCA who failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively). Patients with sensitizing mutations/alterations/rearrangements are eligible if received 1 or more SOC agent/s targeting these mutations unless not a candidate for these therapies
  • Mesothelioma patients who have received at least 1 SOC therapy for metastatic/recurrent mesothelioma per NCCN recommendations or not a candidate for SOC therapy

Who cannot take part

  • Uncontrolled inter-current illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias not well controlled with medication, myocardial infarction within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients may not be receiving any other investigational agents, or have participated in any investigational drug study < 28 days prior to starting on the current study
  • History of any other malignancies in the last 2 years except for in-situ cancer, basal or squamous cell skin cancer treated with curative intent
  • Males and females unable to adhere to abstinence or use highly effective methods of contraception (annual failure rate < 1%) to prevent study subjects' pregnancy or study subjects' partner pregnancy
  • Uncontrolled or untreated CNS metastases and treated CNS metastases are allowed, as long as the patient is clinically stable
  • Presence carcinomatous meningeal involvement
  • Since the teratogenic potential of AG01 is currently unknown, females who are pregnant or lactating are excluded

Where in United States

  • University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United StatesContact: Katherine Tkaczuk, MDTaking people

About the trial

What the trial wants to find out

This is a first in human phase 1 study of AG01 an anti-Progranulin/Glycoprotein88 (PGRN/GP88) antibody in patients with advanced solid tumors. AG01 is a recombinant monoclonal antibody expressed in a CHO production cell line. The antibody AG01 binds to human PGRN/GP88, expressed on cancer cells.

Read full original descriptionShow less

This study will have a dose escalation portion (1A) to evaluate maximum tolerated dose (MTD) and/or maximum administered dose (MAD), the safety and tolerability of AG01treatment before the dose expansion portion (1B) of the study is initiated. The dose escalation portion of this study (1A) will also be used to determine the recommended phase 2 dose (RP2D) of AG01 antibody to be evaluated in the cohort expansion portion (1B).

The 5 groups in the trial

  • AG-01 treated group phase 1ATreatment being tested

    For dose escalation, subjects will be treated with increasing doses of AG01 from 1 mg/kg to 8 mg/kg. The duration of each treatment cycle is 28 days with two infusions of AG01 every 14 days.

    Treatment: AG-01 Compound

  • AG-01 1B triple negative breast cancer treated groupTreatment being tested

    TNBC is defined as ER and/or PR \< 1% by IHC, HER2 \<3+ by IHC and/or FISH negative, subjects must have received 1 or more standard of care (SOC) therapies for metastatic TNBC. If PD(L)1-positive, must have received a combination of chemotherapy and a PD (L)-1 agent (Pembrolizumab), unless not a candidate for these therapies If gBRCA 1 or 2 mutation is present, must have received SOC therapies including a PARPi, unless not a candidate for these therapies. Sacituzumab Govitecan ADC is FDA approved for treatment of advanced TNBC, prior exposure to this therapy does not preclude eligibility in the current study.

    Treatment: AG-01 Compound

  • AG-01 1B Hormone-resistant breast cancerTreatment being tested

    Hormone-resistant breast cancer is defined as, ER and/or PR \>1%, HER2 \<3+ by IHC and/or FISH negative, received 1 or more hormonal (HT) therapies or HT/CD4/6 kinase inhibitor or HT/MTOR inhibitor for treatment of metastatic breast cancer. If the tumor has known PIK3CA mutation, HT/Alpelisib combination should be considered unless not a candidate for this therapy.

    Treatment: AG-01 Compound

  • AG-01 1B NSCLCTreatment being tested

    Subjects with metastatic/recurrent NSCLCA failed 2 or more SOC therapies, including platinum-based chemotherapy and an anti-PD (L) -1 agent (sequentially or consecutively), Subjects with sensitizing mutations/alterations/rearrangements are eligible if received 1 or more SOC agent/s targeting these mutations unless not a candidate for these therapies.

    Treatment: AG-01 Compound

  • AG-01-1B mesotheliomaTreatment being tested

    Subjects with mesothelioma who received at least 1 SOC therapy for metastatic/recurrent mesothelioma per NCCN guidelines or not a candidate for SOC therapy.

    Treatment: AG-01 Compound

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
FIH Phase 1A /1B Study of AG01 Antibody Against Progranulin/GP88 in Advanced Solid Tumor Malignancies With Expansion Cohorts in Advanced Triple Negative Breast Ca, Hormone Resistant Breast Ca, Non Small Cell Lung Cancer and Mesothelioma
Plain-language title
Tests AG01 antibody in advanced solid tumors, including breast and lung cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 November 2022